The Impact of Selective Serotonin Reuptake Inhibitors on Bleeding Risk: A Comprehensive Review

Ktsdesign/AdobeStock

Selective serotonin reuptake inhibitors (SSRIs) have revolutionized the treatment of depression and anxiety disorders, offering significant improvements in patient outcomes with a relatively favorable adverse effect profile compared with older antidepressants such as tricyclic antidepressants and monoamine oxidase inhibitors.^1,2 SSRIs, which include widely used medications such as fluoxetine, sertraline, and paroxetine, function by selectively inhibiting the reuptake of serotonin (5-HT) into presynaptic neurons, thereby increasing its availability in the synaptic cleft and enhancing serotonergic neurotransmission.^3,4

Despite their therapeutic benefits, SSRIs have been linked to an increased risk of bleeding, which is particularly concerning given their widespread use. Platelets play a critical role in hemostasis by forming clots to stop bleeding at sites of vascular injury. Serotonin stored in platelets is essential for proper platelet function and aggregation.⁵ When platelets adhere to damaged blood vessels, they release serotonin and other substances that promote further platelet activation and aggregation, forming a primary hemostatic plug.^6,7

The mechanism by which SSRIs influence bleeding risk involves the inhibition of serotonin reuptake into platelets, leading to reduced intracellular serotonin levels. This reduction impairs platelet aggregation and disrupts the normal hemostatic process.⁸ Several studies have explored this mechanism and its clinical implications, highlighting the need for careful management of patients on SSRIs, particularly those with additional risk factors for bleeding.^9,10

This review aims to synthesize current research on the interaction between SSRIs and platelet function, assess the clinical implications of SSRI-associated bleeding risks, and offer practical recommendations for health care providers managing patients on SSRIs. By examining the underlying mechanisms, clinical evidence, and management strategies, this review seeks to provide a comprehensive understanding of the bleeding risks associated with SSRIs and inform clinical practice.

Methods

A comprehensive literature review was conducted using sources from PubMed, Medline, and other reputable databases. Studies included in this review were selected based on their relevance to the impact of SSRIs on platelet function and bleeding risk. Key studies examining the mechanisms, clinical outcomes, and recommendations for managing bleeding risk in patients taking SSRIs were analyzed. The review also incorporates expert consensus and clinical guidelines where available.

Mechanism of Action

SSRIs exert their therapeutic effects by selectively inhibiting the serotonin transporter (SERT), which is responsible for the reuptake of serotonin (5-HT) from the synaptic cleft back into presynaptic neurons.^3,4 By blocking this transporter, SSRIs increase the availability of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission, which is beneficial in alleviating symptoms of depression and anxiety disorders.^3,4 However, this mechanism also impacts platelets, which contain SERT and store approximately 99% of the body's serotonin.⁵ Platelets acquire serotonin from the bloodstream through SERT, which plays a crucial role in platelet aggregation, an essential process in primary hemostasis.⁶ When platelets adhere to a site of vascular injury, they release serotonin along with other mediators like adenosine diphosphate (ADP) and calcium, which promote further platelet activation and aggregation, forming a primary hemostatic plug.^7,8

Several studies have elucidated the specific impact of SSRIs on platelet function. For example, the study by Maurer-Spurej et al demonstrated that SSRIs significantly reduce serotonin levels in platelets by inhibiting their reuptake.⁵ This depletion of serotonin impairs the platelets' ability to aggregate effectively. Furthermore, Maurer-Spurej et al found that serotonin is not a direct agonist for platelet aggregation but a helper agonist.⁵ It potentiates the response of platelets to other agonists like ADP and thrombin, which are critical for amplifying the aggregation process. In addition to inhibiting serotonin reuptake, SSRIs also affect the expression of surface glycoproteins on platelets, which are essential for their activation and aggregation. For instance, the study by Halperin et al showed that the reduction of platelet serotonin levels by SSRIs leads to decreased expression of glycoprotein IIb/IIIa and P-selectin, both of which are critical for platelet adhesion and aggregation.⁷

McCloskey provided further insight into the specific effects of SSRIs on platelet function, emphasizing that measuring platelet function can help understand the bleeding risks associated with these medications.¹¹ By monitoring platelet function in the presence of various platelet aggregation agonists, this study elucidated which of these were most impacted by SSRIs.

Specifically, arachidonic acid and collagen’s agonistic effects were significantly reduced by SSRIs. Notably, this was determined by a change in aggregation percent, determined by lumi-aggregometry, whereas a PFA-100 demonstrated insignificant results.This study highlights the importance of monitoring the subtle changes in platelet function in patients on SSRIs to mitigate bleeding risks.

Clinical Implications

The clinical implications of impaired platelet function due to SSRIs are significant. Various studies have shown increased bleeding risks in different patient populations. For instance, a comprehensive review by Edinoff et al highlights that SSRIs are associated with higher rates of bleeding complications in surgical patients, those with liver disease, and postpartum women.⁸ Additionally, the concomitant use of SSRIs with other anticoagulant or antiplatelet medications, such as NSAIDs or warfarin, exacerbates the risk, as noted in the study by De Abajo et al.⁹ This necessitates a cautious approach in managing patients who require SSRIs alongside other medications that influence hemostasis.

McFarland discussed considerations for consult-liaison psychiatrists regarding SSRI bleeding risks, particularly in complex clinical scenarios involving multiple medications.¹² This publication emphasizes the need for interdisciplinary collaboration and careful management of patients on SSRIs, especially in hospital settings where multiple medications are often administered.

Risk Factors and Patient Populations

Certain patient populations are at a higher risk of bleeding when using SSRIs. Older adults, for example, are more susceptible to bleeding complications, especially when undergoing surgery or taking multiple medications. This was evidenced in the study by Movig et al, which showed an increased incidence of bleeding events in patients on SSRIs, particularly when combined with warfarin.¹⁰ Moreover, patients with cardiovascular disease, who are often on antiplatelet therapy, face a compounded risk of bleeding. It is crucial to monitor these patients closely and consider alternative therapies where appropriate.^13,14 Additionally, Halperin and Reber noted the influence of antidepressants on hemostasis, emphasizing the need for careful patient management.⁷ Serebruany et al explored the relationship between the release of platelet/endothelial biomarkers and SSRI use, highlighting the need for close monitoring in patients with cardiovascular conditions.¹⁵

Zagaria provided insights into the bleeding risks associated with SSRI use in surgical patients and seniors, underscoring the importance of tailored management strategies for these vulnerable populations.¹⁶ The publication stresses that elderly patients, due to their increased vulnerability, require special consideration when prescribed SSRIs, particularly in the perioperative setting.

In patients with critical illness, preadmission SSRI use was linked to higher in-hospital mortality, particularly in those with acute coronary syndrome or admitted to cardiac surgery recovery units. Notably, this was seen with an affinity-correlated effect, where higher affinity SSRIs paroxetine and sertraline demonstrated significantly higher mortalities. Importantly, this study did not find a mechanism for this and did note that there was not a significant difference in blood transfusion, suggesting bleeding risk may not be the cause.¹⁷

Comparative Risks Among SSRIs

Not all SSRIs carry the same risk for bleeding. Medications with higher serotonin reuptake inhibition, such as fluoxetine, paroxetine, and sertraline, present a greater risk compared with those with lowera ffinity, like mirtazapine or bupropion.¹⁴ This was highlighted in the retrospective analysis by Andrade et al, which found a correlation between serotonin transporter binding affinity and the magnitude of bleeding risk.¹³ Clinicians should consider this variability when prescribing SSRIs, particularly for patients already at high risk for bleeding.¹⁸ The influence of serotonin transporter polymorphisms on SSRI efficacy and adverse effects, as described by Silva et al, further emphasizes the complexity of SSRI management.¹⁸ Furthermore, Serebruany et al indicated the need to monitor plasma levels of SSRIs and their metabolites in relation to platelet and endothelial biomarkers, underscoring the variability in bleeding risks among different SSRIs.¹⁵

Gahr specifically examined the impact of serotonin transporter binding affinity on the risk of bleeding related to antidepressants, providing valuable insights for clinical decision-making.²⁰ The study supports the notion that SSRIs with higher binding affinity to the serotonin transporter pose a greater risk of bleeding, thus necessitating cautious use in high-risk patients.

Management Strategies

Managing the bleeding risk associated with SSRIs involves a multifaceted approach. Clinical recommendations suggest monitoring patients for signs of bleeding, especially during the initiation of SSRI therapy or when used in combination with other anticoagulants. The use of proton pump inhibitors (PPIs) can mitigate the risk of gastrointestinal bleeding, as recommended in the study by Loke et al.⁴ Furthermore, the decision to discontinue SSRIs prior to surgical procedures should be individualized based on the patient's overall risk profile and the specific circumstances of their treatment.²¹ The relationship between SSRI use and clinically relevant bleeding in patients on warfarin was also examined by Wallerstedt et al, highlighting the importance of monitoring such interactions.¹⁹

Lee emphasized the necessity of monitoring when SSRIs are used concomitantly with NSAIDs or NOACs due to the increased risk of bleeding.²² The study points out that the combination of these medications significantly elevates bleeding risk, thus requiring diligent patient monitoring and possibly adjusting medication regimens.

Hoirisch-Clapauch discussed the broader implications of antidepressant use, highlighting the dual risks of bleeding and thrombosis and underscoring the need for comprehensive patient assessment and management strategies.²³ This publication suggests that while SSRIs are generally associated with bleeding, their effect on thrombosis must also be considered, particularly in patients with underlying thrombotic disorders.

Discussion

The reviewed literature consistently indicates that SSRIs increase bleeding risk primarily through their impact on platelet function. By inhibiting the reuptake of serotonin into platelets, SSRIs reduce platelet serotonin levels, impairing platelet aggregation and primary hemostasis. This mechanism explains the increased bleeding risks observed in various clinical scenarios, including surgical settings, postpartum periods, and among patients with liver disease or concomitant use of other anticoagulant or antiplatelet medications.^14,7

Given these findings, clinicians must carefully balance the benefits of SSRI therapy with the potential risks of bleeding. This is particularly crucial for patients who are already at increased risk for bleeding due to other medical conditions or medications. Clinical decisions should be individualized, considering the patient's overall risk profile, the necessity of SSRI therapy, and the potential for alternative treatments.¹³ The evidence also suggests that the degree of serotonin reuptake inhibition correlates with bleeding risk. Therefore, selecting SSRIs with lower serotonin binding affinities or considering alternative antidepressants may be prudent for patients at high risk for bleeding. Additionally, concomitant medications that further increase bleeding risk, such as NSAIDs, warfarin, or NOACs, should be used with caution, and patients should be closely monitored for signs of bleeding.^14,15

Concluding Thoughts

SSRIs significantly impact platelet function by reducing serotonin reuptake, leading to impaired platelet aggregation and increased bleeding risk. Clinicians must be vigilant when prescribing SSRIs, especially for patients with additional risk factors for bleeding. Further research is needed to elucidate the dose-response relationship and to develop comprehensive guidelines for managing bleeding risks in patients on SSRIs. Until then, individualized clinical decision-making and careful monitoring remain essential to minimize the risk of adverse bleeding events.

Mr Gupta is a third year medical student at EnMed, with a BS in Chemical Engineering and a Global Medical Innovation focused Master’s in Bioengineering both from Rice University. He has work experience in medical device development in the neurosurgical shunt space and cardiac catheter space. Ms Hakam is a medical student at Texas A&M School of Engineering Medicine. As a medical student at Texas A&M’s EnMed program, she conducts research in nanomedicine drug delivery systems and postpartum mental health, while serving as an Aggie Ambassador, UH Pre-Medicine mentor, and Treasurer of A&M's TMA/AMA. With a passion for bridging engineering and medicine, she aims to advance psychiatric care through psychopharmacology, bioinformatics, and novel treatment delivery systems. Mr Nisar is a medical student at Texas A&M School of Engineering Medicine. Dr D’Empaire is a psychiatrist and supervisor for Texas A&M University Medical students with the EnMed Program. Dr Jamal is a psychiatrist based in Houston, TX. Dr Safavi is an assistant professor of Psychiatry & Behavioral Sciences at Baylor College of Medicine and attending physician at Methodist Hospital, Houston.

References

1. Ferguson JM. Ssri antidepressant medications: adverse effects and tolerability.PrimCareCompanionJClinPsychiatry. 2001;3(1):22-27.

2. SkopBP,BrownTM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37(1):12-16.

3. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59-64.

4. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31-40.

5. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91(1):119-128.

6. Li N, Wallén NH, Ladjevardi M, et al. Effects of serotonin on platelet activation in whole blood.BloodCoagulation&Fibrinolysis. 1997;8(8):517-524.

7. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues inClinicalNeuroscience. 2007;9(1):47-59.

8. Edinoff AN, Raveendran K, Colon MA, et al. Selective serotonin reuptake inhibitors and associated bleeding risks: a narrative and clinical review. Health Psychol Res. 2022;10(4):39580.

9. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106-1109.

10. Cochran KA, Cavallari LH, Shapiro NL, et al. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433-438.

11. McCloskey DJ, Postolache TT, Vittone BJ, et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res. 2008;151(3):168-172.

12. McFarland D, Merchant D, Khandai A, et al. Selective serotonin reuptake inhibitor (SSRI) bleeding risk: considerations for the consult-liaison psychiatrist. Curr Psychiatry Rep. 2023;25(3):113-124.

13. Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575.